Evidence map›Paper›PMID 39853402›Full record

Trial reportCancer chemotherapy and pharmacology2025

Lipidomic profiling of plasma from patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1).

Masaki Ri, Shinsuke Iida, Kosuke Saito, Yoshiro Saito, Dai Maruyama, Arisa Asano, Suguru Fukuhara, Hideki Tsujimura, Kana Miyazaki, Shuichi Ota and 21 more

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Cancer chemotherapy and pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The role of phosphatidylcholine metabolism in tumors.Medical oncology (Northwood, London, England) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Masaki RiDepartment of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan. rrmasaki@med.nagoya-cu.ac.jp.
Shinsuke IidaDepartment of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan.
Kosuke SaitoDivision of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan.
Yoshiro SaitoDivision of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan.
Dai MaruyamaDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Arisa AsanoDepartment of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan.
Suguru FukuharaDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Hideki TsujimuraDepartment of Hematology and Medical Oncology, Chiba Cancer Center, Chiba, Japan.
Kana MiyazakiDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan.
Shuichi OtaDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Noriko FukuharaDepartment of Hematology, Tohoku University Hospital, Sendai, Japan.
Eiju NegoroDepartment of Hematology and Oncology, University of Fukui Hospital, Fukui, Japan.
Junya KurodaDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Shinichiro YoshidaDepartment of Hematology, NHO Nagasaki Medical Center, Nagasaki, Japan.
Eiichi OhtsukaDepartment of Hematology, Oita Prefectural Hospital, Oita, Japan.
Tsukamoto NorifumiDepartment of Hematology, Gunma University, Maebashi, Japan.
Takayuki TabayashiDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Nobuyuki TakayamaDepartment of Hematology, Kyorin University Faculty of Medicine, Mitaka, Japan.
Toko SaitoDepartment of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan.
Yasuhiro SuzukiDepartment of Hematology, NHO Nagoya Medical Center, Nagoya, Japan.
Yasuhiko HaradaDepartment of Hematology, Toyota Kosei Hospital, Toyota, Japan.
Ishikazu MizunoDivision of Hematology, Hyogo Cancer Center, Akashi, Japan.
Isao YoshidaDepartment of Hematologic Oncology, NHO Shikoku Cancer Center, Matsuyama, Japan.
Masaki MarutaDepartment of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Matsuyama, Japan.
Yasushi TakamatsuDivision of Medical Oncology, Hematology and Infectious Diseases, Fukuoka University Hospital, Fukuoka, Japan.
Hiroo KatsuyaDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Makoto YoshimitsuDepartment of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.
Yosuke MinamiDepartment of Hematology, National Cancer Center Hospital East, Kashiwa, Japan.
Keisuke KanatoJCOG Data Center/Operating Office, National Cancer Center Hospital, Tokyo, Japan.
Wataru MunakataDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Hirokazu NagaiDepartment of Hematology, NHO Nagoya Medical Center, Nagoya, Japan.

Funding

Grant-in-Aid for Clinical Cancer Research from the Ministry of Health, Labour and Welfare of Japan (H26-kakushin-teki-gan-ippan-074)National Cancer Center Research and Development Fund (26-A-4, 29-A-3, 2020-J-3, 2023-J-03)Practical Research for Innovative Cancer Control from the Japan Agency for Medical Research and Development, AMED JP16ck0106077 and JP19ck0106348.
6 · The paper itself

Abstract

purposeA comprehensive analysis of metabolites (metabolomics) has been proposed as a new strategy for analyzing liquid biopsies and has been applied to identify biomarkers predicting clinical responses or adverse events associated with specific treatments. Here, we aimed to identify metabolites associated with bortezomib (Btz)-related toxicities and response to treatment in newly diagnosed multiple myeloma (MM).

methodsFifty-four plasma samples from transplant-ineligible MM patients enrolled in a randomized phase II study comparing two less-intensive regimens of melphalan, prednisolone and Btz (MPB) were subjected to the lipidomic profiling analysis. The amount of each lipid metabolite in plasma obtained prior to MPB therapy was compared to toxicity grades and responses to MPB therapy.

resultsHigh levels of 7 phospholipids (4 lysophosphatidylcholines and 3 phosphatidylcholines) were observed in cases with Btz-induced ≥ grade 2 peripheral neuropathy (BiPN) (n = 11). In addition, low levels of 3 fatty acids (FAs)-FA (18:2), FA (18:1), and FA (22:6)-were observed in patients who developed severe skin disorders ≥ grade 2 (n = 10). No metabolite significantly associated with treatment response was identified.

conclusionWe conclude that levels of specific plasma lipid metabolites are associated with the severity of BiPN and skin disorders in patients with MM. These metabolites may serve as candidate biomarkers to predict Btz-induced toxicity in patients with MM before initiating Btz-containing therapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBortezomibLipidomicsLipidsMultiple MyelomaAgedAged, 80 and overBiomarkersBiomarkers, TumorFemaleHumansMaleMelphalanMiddle AgedPeripheral Nervous System DiseasesPrednisoloneBiomarkersBiomarkers, TumorBortezomibLipidsMelphalanPrednisoloneBortezomibLipidomicsMultiple myelomaPeripheral neuropathyPlasma

Identifiers

PMID39853402

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.